New York State Common Retirement Fund Reduces Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL)

New York State Common Retirement Fund lowered its position in QuidelOrtho Co. (NASDAQ:QDELFree Report) by 9.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 101,580 shares of the company’s stock after selling 10,877 shares during the quarter. New York State Common Retirement Fund owned about 0.15% of QuidelOrtho worth $7,419,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Money Concepts Capital Corp grew its holdings in shares of QuidelOrtho by 66.8% in the fourth quarter. Money Concepts Capital Corp now owns 337 shares of the company’s stock valued at $29,000 after purchasing an additional 135 shares during the period. Global Retirement Partners LLC grew its holdings in shares of QuidelOrtho by 109.0% in the third quarter. Global Retirement Partners LLC now owns 347 shares of the company’s stock valued at $26,000 after purchasing an additional 181 shares during the period. Arizona State Retirement System grew its holdings in shares of QuidelOrtho by 1.4% in the third quarter. Arizona State Retirement System now owns 14,229 shares of the company’s stock valued at $1,039,000 after purchasing an additional 200 shares during the period. Eagle Bay Advisors LLC grew its holdings in shares of QuidelOrtho by 174.2% in the second quarter. Eagle Bay Advisors LLC now owns 351 shares of the company’s stock valued at $34,000 after purchasing an additional 223 shares during the period. Finally, Oak Family Advisors LLC grew its holdings in shares of QuidelOrtho by 1.6% in the second quarter. Oak Family Advisors LLC now owns 16,771 shares of the company’s stock valued at $1,390,000 after purchasing an additional 263 shares during the period. Hedge funds and other institutional investors own 93.87% of the company’s stock.

QuidelOrtho Trading Up 1.7 %

NASDAQ QDEL opened at $68.15 on Friday. The firm has a 50 day simple moving average of $70.94 and a 200-day simple moving average of $72.17. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.95 and a current ratio of 1.59. QuidelOrtho Co. has a one year low of $57.54 and a one year high of $98.67. The firm has a market cap of $4.55 billion, a price-to-earnings ratio of 358.70 and a beta of 0.21.

Analyst Ratings Changes

Several brokerages have weighed in on QDEL. William Blair reaffirmed an “outperform” rating on shares of QuidelOrtho in a research note on Thursday, November 2nd. Raymond James lowered their target price on shares of QuidelOrtho from $110.00 to $100.00 and set a “strong-buy” rating for the company in a research note on Thursday, November 2nd. Royal Bank of Canada lowered their target price on shares of QuidelOrtho from $140.00 to $130.00 and set an “outperform” rating for the company in a research note on Thursday, December 21st. Finally, Citigroup reaffirmed a “neutral” rating and set a $72.00 target price (down previously from $95.00) on shares of QuidelOrtho in a research note on Monday, December 11th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, QuidelOrtho currently has an average rating of “Moderate Buy” and an average price target of $96.75.

Get Our Latest Research Report on QDEL

QuidelOrtho Company Profile

(Free Report)

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.

Recommended Stories

Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuidelOrtho Co. (NASDAQ:QDELFree Report).

Institutional Ownership by Quarter for QuidelOrtho (NASDAQ:QDEL)

Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.